Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study

Fig. 2

The detailed clinical, treatment and outcome information of patients with HCQ/CQ treatment. HCQ hydroxychloroquine, CQ chloroquine, ESR erythrocyte sedimentation rate, hsCRP high sensitivity C reactive protein, IL-6 interleukin-6, TCM traditional Chinese Medicine, GCs glucocorticoids. Comorbidities refers to the types of comorbidities in one single patient. Disease severity was classified according to the Chinese management guideline for COVID-19. Disease duration (days) was calculated from symptom onset to inpatient department admission. GCs were summed as methylprednisolone or equivalent and the total dosages of GCs were recorded in the corresponding square, respectively. Patient No.10 had transient first-degree atrioventricular block (AVB). Patient No.12 complained about dizziness and blurred vision which disappeared after CQ discontinuation. Patient No.14 had recurrent AVB and obvious QTc elongation even after CQ withdrawn. The virus shedding period was defined from symptoms onset to the first day of the consecutive negative PCR results before discharge. The X was put in the square in which the data was not available

Back to article page